lunes, 26 de octubre de 2026

Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Press releaseGlobeNewswire· March 28, 2026

Tribal Loans Are On The Rise — And TribalLoans.com Might Be the Reason Why

View original at globenewswire.com

Tribal Loans Are On The Rise — And TribalLoans.com Might Be the Reason Why New York, NY, March 27, 2026 (GLOBE NEWSWIRE) -- Let's be honest…

Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

Platform runs only soft credit inquiry that won't leave a mark on credit file
60% confidence
Application process takes around two minutes
60% confidence
Approved applicants can receive funds via ACH transfer on the day they apply
60% confidence
Platform has a 4.9 out of 5 customer rating
60% confidence
TribalLoans.com has served over 2,000,000 borrowers across the US
60% confidence

Citado en estos reportajes de Via News

Lo que sabemos · la inteligencia detrás de esta página

En vivo desde el sustrato

Lo que estamos viendo

Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings

Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.

Nuestra lectura de los datos ›

Señales que seguimos

EPKINLY Regulatory-Clinical Success Cascade

High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.

Patrones que observamos ›

Donde las fuentes discrepan

Ford Motor Company

Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.

Señalamos los conflictos abiertamente ›

Verificado recientemente

✓ Verificado con la fuente original

4,994

hechos rastreados a su fuente — y señalamos los que no se sostienen.

101 entidades seguidas4,994 hechos verificados con la fuente5,500 documentos fuente archivados

Consulta estos datos → isubstrate.com